CRYOPDP | Part of DHL Health Logistics

Market trends shaping CRO and CDMO logistics

When more depends on the same shipment, logistics needs to be planned, visible and controlled from the start.

	MARKET TREND	IMPACT ON CROs & CMOs	LOGISTICS IMPLICATIONS
1 What's changing in the market?	**CRO and CDMO outsourcing is growing.**	More clinical development, manufacturing and testing work is being managed through external partners.	More sensitive materials need to move between different teams, facilities, sites and countries.
2 What is becoming more complex?	**Trials and therapies are becoming more specialised.**	Oncology, biologics, advanced therapies and personalised medicine can involve stricter handling needs, tighter timelines and temperature-control requirements.	The shipment is not just a delivery. It may be carrying material that is sensitive, time-critical or difficult to replace.
3 What is becoming more distributed?	**Clinical activity is moving across more locations.**	Trial-related activities may involve clinical sites, local healthcare providers, labs, depots, manufacturing teams and patient-facing locations.	More locations mean more handovers, more coordination and more points where timing, documentation or temperature control can be questioned.
4 Where does the pressure appear?	**Clinical trial supply and logistics are becoming more time-sensitive and temperature-controlled.**	A shipment may be linked to a patient visit, lab result, quality review, production step or release decision.	A delay, a temperature concern, or a missing record can affect the teams waiting to act.
5 What needs to be controlled?	**Visibility and control are becoming more important in sensitive clinical and pharmaceutical supply chains.**	They need logistics processes that support timing, temperature, records, escalation and chain of custody.	Sensitive shipments need to be planned, visible, documented and controlled before, during and after transport.

Sources: Fortune Business Insights, IQVIA Institute, Precedence Research, FDA guidance on decentralised clinical trials, Clinical Supply Leader.